You are reading the English version
קרא בעברית
Androgenetic alopecia is the single most common cause of hair loss in men, yet most people who notice a receding hairline or thinning crown have no clear understanding of the biological mechanism driving it. The condition is progressive, genetically encoded, and hormone-dependent – meaning it will not resolve on its own without intervention. This guide explains the science behind DHT-driven follicle miniaturization, walks through each stage of the Norwood Scale, maps treatment options to each stage, and clarifies when medical therapy is sufficient versus when a hair transplant becomes the most effective path to permanent restoration.
What Is Androgenetic Alopecia?
Androgenetic alopecia is a genetically determined, androgen-dependent condition that causes progressive hair follicle miniaturization, affecting approximately 50% of men by age 50 and up to 80% by age 80.
The term itself describes the two forces at work: “androgenetic” combines “androgen” (the class of hormones that includes testosterone and DHT) with “genetic” (the inherited sensitivity that determines which follicles respond to those hormones). “Alopecia” is the clinical term for hair loss. Unlike telogen effluvium or alopecia areata, androgenetic alopecia is not triggered by a single event – it is a continuous process that begins as soon as genetically susceptible follicles are exposed to circulating androgens, typically during or after puberty.
The condition follows a predictable pattern in men. Hair loss begins at the temples and the mid-frontal scalp, creating the familiar “receding hairline.” Simultaneously or shortly afterward, thinning develops at the vertex (crown). Over years or decades, these two zones expand and merge until only a horseshoe-shaped band of hair remains on the sides and back of the head. This remaining hair – the donor area – is genetically resistant to DHT, which is the biological foundation that makes hair transplant surgery possible.
Androgenetic alopecia produces no pain or systemic health effects. However, its psychological impact is well-documented: clinical studies consistently link male pattern baldness to reduced self-esteem and social anxiety, with effects strongest when hair loss begins before age 30. The condition is progressive without intervention – no case spontaneously reverses – and the rate of progression varies widely based on genetics.
How DHT Causes Male Pattern Baldness
Dihydrotestosterone (DHT), converted from testosterone by the enzyme 5-alpha reductase, binds to androgen receptors in genetically susceptible follicles, shortening the growth phase and progressively shrinking each hair until the follicle produces only vellus (invisible) hair.
Testosterone circulates through the bloodstream and reaches scalp tissue, where 5-alpha reductase (primarily the Type II isoform) converts it into DHT – a hormone roughly five times more potent at binding androgen receptors. In follicles with a high density of these receptors, DHT triggers signals that progressively shorten the anagen (growth) phase.
A healthy follicle grows for two to seven years, producing a thick terminal hair. Under DHT influence, that same follicle’s anagen phase may shorten to one year, then six months, then weeks. Each cycle produces a thinner, shorter, lighter hair – a process called follicular miniaturization. Under dermoscopy, this appears as a mix of thick terminal hairs and thin vellus hairs in the same area.
DHT does not affect all follicles equally. Follicles on the top and front of the scalp are genetically programmed to respond to DHT; follicles on the sides and back are not. This selective vulnerability explains the characteristic pattern of male baldness – and is the reason hair transplant procedures produce permanent results. Transplanted follicles from the DHT-resistant donor area retain their resistance in their new location.
Finasteride inhibits Type II 5-alpha reductase, reducing scalp DHT by approximately 60-70%. Dutasteride inhibits both Type I and Type II isoforms, reducing DHT by over 90%. Both can slow or halt miniaturization in active follicles but cannot revive follicles that have already fibrosed. For a deeper explanation, see our complete guide to DHT and hair loss.
Stages of Androgenetic Alopecia – The Norwood Scale
The Norwood Scale classifies male pattern baldness into seven stages, from minimal temple recession (Stage I) to near-total vertex and frontal baldness (Stage VII).
Developed by Dr. O’Tar Norwood in 1975 as a refinement of the Hamilton classification, it remains the standard used by dermatologists and hair transplant surgeons to assess loss, plan graft requirements, and set expectations. Understanding your Norwood stage is critical for treatment planning.
| Norwood Stage | Description | Typical Appearance | Estimated Grafts for Full Restoration |
|---|---|---|---|
| Stage I | No significant recession | Mature adult hairline; minimal or no visible loss | 0 – no treatment typically needed |
| Stage II | Slight recession at temples | Triangular areas of recession at the frontotemporal region | 500–800 grafts (if desired) |
| Stage III | Deepening temporal recession | Noticeable M-shaped hairline; earliest clinically significant stage | 1,000–1,500 grafts |
| Stage III Vertex | Early crown thinning with moderate frontal recession | Thinning or bald spot at the vertex combined with Stage III frontal pattern | 1,500–2,000 grafts |
| Stage IV | Further frontal and vertex loss with a bridge of hair between zones | Larger bald area at crown; wider frontal recession; band of hair still separates the two zones | 2,000–2,500 grafts |
| Stage V | Bridge between frontal and vertex zones thins significantly | Frontal and crown zones nearly merged; remaining bridge is sparse | 2,500–3,500 grafts |
| Stage VI | Frontal and vertex zones fully merged | Large continuous bald area on top; horseshoe band of hair on sides and back | 3,500–5,000 grafts |
| Stage VII | Most extensive pattern of loss | Only a narrow band of hair remains on sides and low back of head | 5,000–7,000+ grafts (may require multiple sessions) |
Stage III is the threshold at which hair loss becomes cosmetically noticeable – and the stage at which most men first seek treatment. Stages IV and V represent the optimal transplant window: enough loss to justify the procedure, yet sufficient donor hair for meaningful density. At Stages VI and VII, donor supply becomes the limiting factor, and realistic goal-setting with a qualified surgeon is essential.
Genetic Factors and Family History
Androgenetic alopecia is a polygenic condition – the androgen receptor (AR) gene on the X chromosome is the strongest identified risk factor.
Because the X chromosome is inherited from the mother, the long-standing belief that baldness “comes from your mother’s father” has some basis in biology. However, it is incomplete. Genome-wide association studies (GWAS) have identified over 200 genetic loci linked to androgenetic alopecia, spread across both sex chromosomes and autosomes. Variants on chromosome 20p11 (near the PAX1 and FOXA2 genes), for example, show strong independent association with hair loss and are inherited from either parent.
The AR gene, located at Xq11-12, encodes the androgen receptor protein – the molecule that DHT physically binds to inside the follicle cell. Certain variants of this gene produce receptors with higher affinity for DHT, making follicles more responsive to even normal circulating hormone levels.
Other contributing genes regulate 5-alpha reductase activity, Wnt signaling pathways (critical for follicle stem cell activation), and hair cycle duration. The cumulative effect of hundreds of variants determines onset age, progression speed, and ultimate pattern.
Family history across both parental lines remains the most reliable predictor of risk. For more on inheritance patterns, see our guide to genetic factors in hair loss.
Treatment Options by Stage
Treatment effectiveness depends heavily on the stage of androgenetic alopecia at the time of intervention.
| Treatment | Best for Stages | Mechanism | Expected Outcome | Key Considerations |
|---|---|---|---|---|
| Finasteride (1 mg/day) | I–IV | Blocks Type II 5-alpha reductase; reduces scalp DHT ~60–70% | Stops progression in ~86%; regrowth in ~65% at 2 years | Requires ongoing use; sexual side effects in 2–4% (mostly reversible) |
| Dutasteride (0.5 mg/day) | I–IV | Blocks Type I and Type II 5-alpha reductase; reduces DHT ~90% | Superior to finasteride in head-to-head trials | Off-label for hair loss in most countries; longer half-life |
| Minoxidil (topical 5%) | I–V | Vasodilator; prolongs anagen and increases follicle size | Moderate regrowth in ~40%; stabilization in most users | Must be applied continuously; initial shedding phase common |
| Low-Level Laser Therapy (LLLT) | I–IV | Photobiomodulation stimulates cellular metabolism in follicles | Modest improvement; best as adjunct to pharmacotherapy | FDA-cleared devices available; limited standalone efficacy |
| PRP (Platelet-Rich Plasma) | I–IV | Concentrated growth factors injected into scalp | Increased hair count and thickness; variable response rates | Requires repeat sessions; protocol varies by provider |
| FUE Hair Transplant | III–VII | Individual follicular units extracted from donor area and transplanted | Permanent restoration; 90–95% graft survival rate | Donor supply is finite; may require multiple sessions for advanced stages |
| FUT Hair Transplant | III–VII | Strip of donor tissue harvested; follicular units dissected and transplanted | Permanent results; highest graft yield per session | Linear scar in donor area; ideal for large-volume sessions |
Medical Therapy (Stages I–III)
Medical treatments for hair loss are most effective when initiated early – before significant follicle fibrosis has occurred. Finasteride reduces DHT production at the source, while minoxidil works independently by prolonging the growth phase and increasing follicle blood flow. Combining both produces superior results to either alone.
The critical limitation: medical therapy maintains existing follicles but cannot regenerate those that have already fibrosed. Every month of delay allows more follicles to cross from treatable to permanently lost, making early initiation the most cost-effective strategy.
Hair Transplant (Stages III–VII)
Hair transplant surgery becomes the primary treatment when androgenetic alopecia has progressed beyond what medical therapy alone can address. The procedure works by relocating DHT-resistant follicles from the donor area to bald or thinning recipient zones. Because these transplanted follicles retain their genetic resistance to DHT, the results are permanent.
FUE removes individual follicular units one at a time, leaving no linear scar. FUT removes a strip of donor tissue, producing a higher graft yield per session at the cost of a linear scar. For advanced stages (VI–VII), donor supply becomes the limiting factor – typically 6,000 to 8,000 grafts are available for lifetime harvesting.
Combined Approach
The combined approach to hair loss treatment produces the best long-term outcomes. A hair transplant restores density where follicles have permanently closed, while ongoing finasteride and minoxidil protect remaining native hair from further miniaturization.
Frequently Asked Questions
Can Androgenetic Alopecia Be Reversed?
Androgenetic alopecia cannot be cured, but it can be effectively managed at every stage. Finasteride and minoxidil can partially reverse miniaturization in active follicles. However, follicles that have fully fibrosed cannot be reactivated by any medication. For permanently lost areas, a hair transplant is the only option that restores visible hair.
At What Age Does Male Pattern Baldness Typically Start?
Androgenetic alopecia can begin at any point after puberty. Approximately 25% of affected men notice visible recession by age 25, 50% by age 50, and up to 80% by age 80. Earlier onset does not always predict rapid progression.
Is Androgenetic Alopecia the Same as Going Bald?
Androgenetic alopecia is the medical term for the hormonally driven process that causes male pattern baldness – but not all baldness is androgenetic alopecia. “Going bald” could describe hair loss from alopecia areata, telogen effluvium, traction alopecia, or scarring alopecia. The distinction matters because treatment depends on the cause.
Related Resources
Am I a Good Candidate for a Hair Transplant?
Not every man with androgenetic alopecia is an immediate candidate for surgery. Age, Norwood stage, donor density, progression rate, and realistic expectations all influence candidacy. Our hair transplant candidate evaluation guide walks through every criterion surgeons assess.
What Causes Hair Loss?
Androgenetic alopecia is the most common cause of hair loss, but autoimmune conditions, hormonal imbalances, nutritional deficiencies, medications, and stress can all cause significant thinning. See our guide to what causes hair loss for a breakdown of every major type.
You are reading the English version
קרא בעברית